AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
Go back to AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder| AbbVie (NYSE: ABBV) | Delayed: 234.85 +4.84 (2.10%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $230.01 | 52 Week High | $68.12 | |||
| Open | $232.97 | 52 Week Low | $50.71 | |||
| Day High | $234.95 | P/E | 50.94 | |||
| Day Low | $231.30 | EPS | $4.61 | |||
| Volume | 2,913,197 | |||||
